Tag : ISATUXIMAB-IRFC

NEWS AND PERSPECTIVE

Isatuximab-irfc + VRd receives FDA approval for NDMM patients ineligible for transplantant
The United States (US) Food and Drug Administration (FDA) has approved the anti-CD38 monoclonal antibody, isatuximab-irfc, in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for transplant.